- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06123377
Angiogenic Factors in the Conservative Management of Gestational Hypertension
April 15, 2024 updated by: Osvaldo A. Reyes T., Saint Thomas Hospital, Panama
Use of Angiogenic Factors in the Conservative Management of Gestational Hypertension. Prospective, Randomised, Controlled Study.
Hypertensive disorders of pregnancy (HPT) are an important cause of maternal-feto-neonatal morbidity and mortality, being one of the three leading causes of maternal death in our country and in developing countries.
The only cure for THE is termination of pregnancy, which ends up being a decision in which gestational age and maternal risks must be balanced.
Angiogenic factors have come to occupy an indispensable place in the arsenal of tools that can be used to separate the patient with a high likelihood of complications from those in whom prolongation of pregnancy could represent an important neonatal benefit.
One of the most controversial scenarios is gestational hypertension, a group of hypertensive disorders considered the mildest form of the pre-eclamptic spectrum, where current recommendations indicate termination of pregnancy at 37 weeks.
However, the decision is based on outdated guidelines developed at a time when angiogenic factors were just beginning to be known.
The purpose of the study is to use angiogenic factors as a guide to decide the most appropriate gestational age for termination of pregnancy in patients diagnosed with gestational hypertension.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
150
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Osvaldo Reyes, MD
- Phone Number: +507 65655041
- Email: oreyespanama@yahoo.es
Study Contact Backup
- Name: Gerado Cardenas, MD
- Email: drgacardenas@hotmial.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Pregnant women between 24 and 40 weeks of gestation.
- Diagnosis of Gestational Hypertension based on ACOG criteria
- index sFlt-1/PIGF equal or below 33
Exclusion Criteria:
- Multiple gestation
- Maternal vasculitis
- Previous cesarean section (3 or more)
- Neurological conditions
- Chronic renal disease
- Purpura
- Heart disease
- Index sFlt-1/PIGF of 34 or more
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 39 weeks
Patients with gestational hypertension and angiogenic factors (sFlt-1/PIGF) below 33 will be evaluated weekly until 39 weeks, when termination of pregnancy will be scheduled.
|
sFLt-1/PGIF below or equal to 33
|
Active Comparator: 37 weeks
Patients with gestational hypertension and angiogenic factors (sFlt-1/PIGF) below 33 will be evaluated weekly until 37 weeks, when termination of pregnancy will be scheduled.
|
sFLt-1/PGIF below or equal to 33
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression to preeclampsia
Time Frame: From the moment of randomization up until delivery. Between 1 and 17 weeks.
|
In subject with gestational hypertension and sFlt-1/PIGF at enrollment equal or below 33, the appearance of proteinuria, severe criteria or sFlt-1/PIGF above 34
|
From the moment of randomization up until delivery. Between 1 and 17 weeks.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maternal / fetal morbidity
Time Frame: Up until discharge. On average, 7 days
|
Presence of any/several indicators of maternal or fetal morbidity (abruptio placenta, HELLP syndrome, eclampsia, fetal growth restriction, acute lung edema).
|
Up until discharge. On average, 7 days
|
Neonatal morbidity
Time Frame: Up until discharge. On average, 3 days
|
Presence of any/several indicators of neonatal morbidity (Apgar scores, admission to NICU, encephalopatic hypoxia)
|
Up until discharge. On average, 3 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
May 1, 2024
Primary Completion (Estimated)
August 15, 2024
Study Completion (Estimated)
September 30, 2024
Study Registration Dates
First Submitted
October 29, 2023
First Submitted That Met QC Criteria
November 2, 2023
First Posted (Actual)
November 8, 2023
Study Record Updates
Last Update Posted (Actual)
April 17, 2024
Last Update Submitted That Met QC Criteria
April 15, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FA022023
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gestational Hypertension
-
University of Mississippi Medical CenterCompletedPregnancy; Proteinuria, With Hypertension (Severe Pre-eclampsia) | Delivery; Proteinuria, With Gestational Hypertension (Pre-eclampsia, Severe) | Pregnancy; Hypertension, Gestational Hypertension, With Albuminuria (Severe Pre-eclampsia)United States
-
Sohag UniversityRecruitingTelocytes in Umbilical Cord of Pregnancies Complicated by Chronic Hypertension, Gestational Hypertension and PreeclampsiaEgypt
-
Mike O'Callaghan Military HospitalWithdrawnGestational Diabetes | Gestational Hypertension
-
Azienda Ospedaliero, Universitaria PisanaRecruitingPre-Eclampsia | Gestational Diabetes | Gestational HypertensionItaly
-
University of Colorado, DenverCompletedPreeclampsia | Gestational Diabetes Mellitus | Gestational Hypertension | Pre-term Delivery | Delivery of Small for Gestational Age (SGA) BabyUnited States
-
Public Health Foundation of IndiaLondon School of Hygiene and Tropical Medicine; Kathmandu University School...Not yet recruitingAnemia | Gestational Diabetes Mellitus (GDM) | Pregnancy Induced Hypertension (PIH)India, Nepal
-
University of ManchesterUnknownGestational Hypertension
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Sunnybrook Research InstituteCompletedGestational HypertensionCanada, United Kingdom, Netherlands, United States, Israel, Australia, Chile, New Zealand, Hungary, Poland, Jordan, Argentina, Brazil, Colombia, Estonia
-
Medical College of WisconsinAdvancing a Healthier Wisconsin Endowment; Food for Health, Inc.Not yet recruitingPreeclampsia | Gestational Diabetes | High Risk Pregnancy | Gestational Hypertension
-
Benha UniversityCompleted
Clinical Trials on Angiogenic factor
-
AHS Cancer Control AlbertaCompleted
-
TheraVitae Ltd.Unknown
-
TheraVitae Ltd.CompletedPeripheral Arterial Disease | Critical Limb IschemiaIsrael
-
TheraVitae Ltd.Mahidol UniversityUnknownCoronary Artery DiseaseIsrael
-
University of ChileCompletedCovid19 | Endothelial Dysfunction | Angiogenesis | Cardiovascular MorbidityChile
-
Centre Hospitalier de PAURecruiting
-
Maastricht University Medical CenterCompleted
-
Pirogov Russian National Research Medical UniversityCompletedVaricose VeinsRussian Federation
-
Tomsk National Research Medical Center of the Russian...CompletedMyocardial InfarctionRussian Federation
-
Fundació Institut de Recerca de l'Hospital de la...Spanish Clinical Research Network - SCReNCompletedPreeclampsia | Intrauterine Growth RestrictionSpain